AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 22 min read$IRMD

Susi Roger E. sold $35K of IRMD (indirect holdings)

Susi Roger E. (CEO, President, Chairman) sold 400 indirectly-held shares of IRADIMED CORP (IRMD) at $88.68 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Susi Roger E.
Published Jun 2, 2026, 6:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 6:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$IRMD
Neutral
medium confidence
Mentioned
$IRMD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRMDNeutralLow
01

Why it matters

The market may briefly note insider selling, but the disclosed pre-arranged 10b5-1 plan typically limits interpretive value versus discretionary selling.

02

Market read

A small, 10b5-1-qualified insider sale is unlikely to drive a sustained repricing without additional fundamental news.

03

What to watch

Check whether there are multiple consecutive insider sales across different officers or changes in trading plan parameters; one small sale alone is low signal.

Relevance 6/10Novelty 6/10Timing: Filed today; sale occurred 2026-06-01 and is disclosed on 2026-06-02.

Background

The article is an SEC Form 4 insider transaction disclosure for IRMD, indicating an open-market sale by a top executive/director/10% owner.

Company-level read

Ticker impact

$IRMDNeutralMedium confidence
Context

IRMD CEO/President/Chairman Susi Roger sold 400 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Likely limited near-term price impact; treat as low-signal unless follow-on selling accelerates or plan details change.

Evidence & confidence

The filing provides a single small sale ($35.5k) and explicitly notes a pre-arranged 10b5-1 plan, which typically dampens market reaction.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated operational/clinical/regulatory catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can be purely mechanical (liquidity/tax) and may not reflect bearish fundamentals.

Key entities

  • issuer
    IRMD

    Iradimed Corp; subject of the insider sale disclosure.

  • insider
    Susi Roger E.

    CEO, President, Chairman; reported an indirect open-market sale under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 8
$IRMDMedAI 9/10

IRadimed (IRMD) Q2 2026 Earnings Call Transcript

IRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.

fool.com7 min
MAY 29
$IRMDMedAI 9/10

Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report

Iradimed Corp (IRMD) reported Q1 2026 results on May 1. The company said revenue rose 13% year over year to $22 million and net income increased 24% to $5.8 million, or $0.45 per share. Iradimed also launched its next-generation 3870 MRI-compatible IV infusion pump in Q1, with shipments expected to begin in Q2. For Q2, it forecast revenue of $20–$21 million and GAAP EPS of $0.40–$0.44; full-year 2026 revenue of $91–$96 million and GAAP EPS of $1.90–$2.05.

finance.yahoo.com4 min